Navigation Links
Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
Date:5/28/2008

Prevalent COPD Population Will Rise by Nearly 19 Percent as a Result of

Increased Diagnosis Rates, According to a New Report from Decision

Resources

WALTHAM, Mass., May 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launches of emerging therapies, especially the long-acting beta2 agonist/inhaled corticosteroid combination drug class, will drive sales in the chronic obstructive pulmonary disease (COPD) drug market to more than $11 billion in 2017.

The new Pharmacor report entitled Chronic Obstructive Pulmonary Disease finds that, among the emerging combination therapies, Novartis/Schering-Plough's indacaterol/mometasone and GlaxoSmithKline/Theravance's GW-642444/GW-685698 will experience annual growth of 60 percent and 71 percent, respectively, between 2012 and 2017 as a result of greater uptake of these once-daily, fixed-dose combination drugs. The market will also be driven by increased diagnosis rates in the next 10 years as the prevalent COPD population will rise by nearly 19 percent as a result of aging populations in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

Although the COPD drug market in 2007 totaled just $6.6 billion, the market has yet to realize its maximum commercial potential, according to the report. Tapping into this great market opportunity will require significant improvements in diagnosis as well as the availability of more effective drug treatments, particularly therapies that address COPD-specific pathology.

"Although disease-modifying therapies are needed, treatments that provide symptomatic relief for COPD will remain the mainstay of treatment through 2017," said Regina Jammen, analyst at Decision Resources. "The market will shift from monotherapy use, as well as from the use of twice-daily dosed therapies, to combination treatments and once-daily dosed therapies as these drugs emerge from clinical development. Each major drug class will see the emergence of new once-daily dosed products, except for drug classes that are exclusively short-acting."

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Computers help chemists fight emerging infections
2. Expert on Emerging Infectious Zoonotic Diseases Joining K-State as a Regents Distinguished Professor
3. iCAD to Present at Americas Growth Capital 4th Annual Emerging Growth Conference
4. GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology
5. Plastic Surgery 2007: Where Truth Behind Emerging Cosmetic Treatments Meets Amazing Reconstructive Advances
6. HealthShares(TM) Announces Change to the HealthShares(TM) Emerging Cancer Index
7. Targets on the horizon: Emerging therapies and novel targets
8. Emerging therapies with a focus on Asian populations mark the AACR Centennial Conference
9. Food and Drug Law Institute, Project on Emerging Nanotechnologies Co-Sponsor Major Conference on Nanotechnology Law, Regulation and Policy
10. OneMedPlace Emerging Healthcare Technologies Finance Forum Jan 7, 8th
11. QED International Associates Announces Changes to the HealthShares(TM) Emerging Cancer Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... BOSTON, MA (PRWEB) , ... May 26, 2017 , ... ... Care Act (AHCA), which narrowly passed the U.S. House on May 4, would result ... would be expected under continued implementation of the 2010 Patient Protection and Affordable Care ...
(Date:5/26/2017)... ... May 26, 2017 , ... Yisrayl Hawkins, Pastor and ... this week that is focusing on the Peace Agreements being discussed by President Donald ... sprint in a race to try to speed up peace talks in the continuous ...
(Date:5/26/2017)... ... May 26, 2017 , ... Rob Lowe acts as host and helps educate ... is on hiking in American. Viewers can reconnect with America as it explores some ... , Many consumers have looked for an inventive new place for a family vacation, ...
(Date:5/26/2017)... ... ... “When the Stars Lead Home”: a poignant story of loss, determination, and perseverance. “When ... avid reader who lives in the Pacific Northwest with her husband, daughter, two dogs, ... She couldn’t be more grateful. , Twelve-year old Tizzy could not believe how quickly ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... year’s recipient of proceeds from its 14th Annual Clays for Kids fundraiser, to ... Road 30, Bennett, Colorado. , As part of BluSky’s partnership with The ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... May 22, 2017  Lilac Corp, the company ... the launch of a new website . ... of a clinical study that showed surprising clearance ... Gene-Eden-VIR/Novirin in individuals suffering from HPV warts, precancerous, ... there are no other treatments that clear the ...
(Date:5/18/2017)... , May 18, 2017  Two Bayer U.S. ... Association (HBA) during its recent 28 th ... City.  The event showcases HBA,s longstanding mission of furthering ... of healthcare. Cindy Powell-Steffen , senior ... U.S. Radiology division, and Libby Howe , a ...
(Date:5/15/2017)... ATLANTA , May 15, 2017  Amy Baxter ... the industry leader in noninvasive pain relief, was awarded ... MM&M magazine. Baxter was recognized at the MM&M ... New York City on May 10, ... helping the biopharma industry go "beyond the pill."  ...
Breaking Medicine Technology: